Brokers Offer Predictions for FDMT FY2027 Earnings

Key Points

• Leerink Partners projects 4D Molecular Therapeutics will report an EPS of ($3.10) for FY2027, which is worse than the current consensus estimate of ($2.84) per share.
• 4D Molecular Therapeutics stock recently rose by 6.3%, with its price reaching $6.54, amid significant trading activity.
• Analysts show mixed ratings on the stock, with one "sell," two "hold," and eight "buy" ratings, reflecting a consensus average rating of "Moderate Buy."

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($3.10) for the year. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

Several other equities analysts have also issued reports on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Tuesday, July 29th. Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday. Roth Capital cut their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday. The Goldman Sachs Group cut their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Barclays cut their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Stock Up 6.3%

FDMT traded up $0.39 during midday trading on Wednesday, reaching $6.54. 119,662 shares of the company's stock were exchanged, compared to its average volume of 871,898. The firm has a market capitalization of $303.00 million, a price-to-earnings ratio of -1.85 and a beta of 2.83. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $17.41. The business has a 50-day simple moving average of $4.50 and a two-hundred day simple moving average of $4.09.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 38.38%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Y Intercept Hong Kong Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $41,000. Los Angeles Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the second quarter valued at about $42,000. AQR Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $46,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $50,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.